JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB198889

Anti-CYP46A1 antibody

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Polyclonal CYP46A1 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human CYP46A1.

View Alternative Names

CYP46, CYP46A1, Cholesterol 24-hydroxylase, CH24H, Cholesterol 24-monooxygenase, Cholesterol 24S-hydroxylase, Cytochrome P450 46A1

2 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP46A1 antibody (AB198889)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP46A1 antibody (AB198889)

Immunohistochemical analysis of paraffin-embedded Human brain tissue labeling CYP46A1 with ab198889 at 1/15 dilution.

Western blot - Anti-CYP46A1 antibody (AB198889)
  • WB

Supplier Data

Western blot - Anti-CYP46A1 antibody (AB198889)

8% SDS-PAGE

All lanes:

Western blot - Anti-CYP46A1 antibody (ab198889) at 1/200 dilution

All lanes:

Human lymphoma tissue lysate at 40 µg

Predicted band size: 56 kDa

false

Exposure time: 1min

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, IHC-P

applications

Immunogen

Synthetic Peptide within Human CYP46A1. The exact immunogen used to generate this antibody is proprietary information.

Q9Y6A2

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/200 - 1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/25 - 1/100", "IHCP-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.4 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CYP46A1 also known as cholesterol 24-hydroxylase is a member of the cytochrome P450 superfamily. It has a molecular mass of approximately 56 kDa. CYP46A1 is expressed mainly in the brain specifically within neurons that are active in cholesterol metabolism. This enzyme localizes in the endoplasmic reticulum and is responsible for converting cholesterol into 24S-hydroxycholesterol a more soluble form that can cross the blood-brain barrier.
Biological function summary

The conversion of cholesterol to 24S-hydroxycholesterol by CYP46A1 helps maintain cholesterol homeostasis in the central nervous system. This process is not part of a large complex but it plays an important role in the clearance of excess cholesterol from the brain. The removal of cholesterol metabolites is essential for normal brain function and neuronal health.

Pathways

CYP46A1's activity fits into the cholesterol catabolism pathway to regulate cholesterol levels specifically in the brain. The enzyme interacts with pathways that include cholesterol turnover and removal from the central nervous system. In this context CYP46A1 is related to APOE a protein involved in lipid metabolism and transport contributing to the balance of cholesterol and lipids in the brain.

Alterations in CYP46A1 have associations with Alzheimer’s disease and Huntington’s disease. In Alzheimer’s disease abnormal cholesterol metabolism involving CYP46A1 may result in the formation of amyloid plaques as the enzyme is linked to APP which is important in the pathology of Alzheimer's. In Huntington’s disease disruption of cholesterol homeostasis by dysregulation of CYP46A1 might aggravate neuronal degeneration suggesting a potential therapeutic target for neuroprotection.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain. Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation (PubMed : 10377398, PubMed : 14640697, PubMed : 18621681, PubMed : 25017465). By promoting constant cholesterol elimination in neurons, may activate the mevalonate pathway and coordinate the synthesis of new cholesterol and nonsterol isoprenoids involved in synaptic activity and learning (By similarity). Further hydroxylates cholesterol derivatives and hormone steroids on both the ring and side chain of these molecules, converting them into active oxysterols involved in lipid signaling and biosynthesis (PubMed : 12077124, PubMed : 14640697, PubMed : 28190002). Acts as an epoxidase converting cholesta-5,24-dien-3beta-ol/desmosterol into (24S),25-epoxycholesterol, an abundant lipid ligand of nuclear NR1H2 and NR1H3 receptors shown to promote neurogenesis in developing brain (PubMed : 25017465). May also catalyze the oxidative metabolism of xenobiotics, such as clotrimazole (PubMed : 20667828).
See full target information CYP46A1

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Oncogene 40:2872-2883 PubMed33742124

2021

Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Samantha A Hutchinson,Alex Websdale,Giorgia Cioccoloni,Hanne Røberg-Larsen,Priscilia Lianto,Baek Kim,Ailsa Rose,Chrysa Soteriou,Arindam Pramanik,Laura M Wastall,Bethany J Williams,Madeline A Henn,Joy J Chen,Liqian Ma,J Bernadette Moore,Erik Nelson,Thomas A Hughes,James L Thorne

Thoracic cancer 11:875-887 PubMed32107851

2020

Circ-IGF1R inhibits cell invasion and migration in non-small cell lung cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Zhanyu Xu,Weiwei Xiang,Wenjie Chen,Yu Sun,Fanglu Qin,Jiangbo Wei,Liqiang Yuan,Liping Zheng,Shikang Li

EMBO molecular medicine 12:e10924 PubMed31777202

2019

Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma.

Applications

Unspecified application

Species

Unspecified reactive species

Mingzhi Han,Shuai Wang,Ning Yang,Xu Wang,Wenbo Zhao,Halala Sdik Saed,Thomas Daubon,Bin Huang,Anjing Chen,Gang Li,Hrvoje Miletic,Frits Thorsen,Rolf Bjerkvig,Xingang Li,Jian Wang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com